Andrew Hollman Meyer - 19 Dec 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Business Officer
Signature
/s/ James Pennington, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
19 Dec 2024
Net transactions value
+$199,985
Form type
4
Filing time
20 Dec 2024, 18:25:16 UTC
Previous filing
27 Sep 2024
Next filing
03 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Options Exercise $199,971 +9,880 +15% $20.24 77,472 19 Dec 2024 Direct
transaction JANX Common Stock Options Exercise $14.02 +1 +0% $14.02 77,473 19 Dec 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Options Exercise $0 -9,880 -9.3% $0.000000 96,870 19 Dec 2024 Common Stock 9,880 $20.24 Direct F1
transaction JANX Stock Option (right to buy) Options Exercise $0 -1 -0% $0.000000 89,999 19 Dec 2024 Common Stock 1 $14.02 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vested on January 1, 2023 and the balance vests in equal monthly installments thereafter over a three year period.
F2 25% of the shares subject to the option vested on January 1, 2024 and the balance vests in equal monthly installments thereafter over a three year period.